• Dr. Dilip Bhuva

    Chief Science and Compliance Officer Xyfil

    Dr Dilip A. Bhuva joined Xyfil Ltd. in Dec, 2014 a then start-up company that manufactures nicotine containing liquids for use in ENDS. Upon his appointment, he was tasked with designing and commissioning various systems that granted data management, production, batch traceability, quality control and quality assurance abilities to ensure production of high quality, consistent and safe products. He was quickly promoted to the post of Chief Science and Compliance Officer and played a vital role in establishing and developing the compliance arm of the business. He currently heads the compliance department and has enabled the company to provide TPD2 services to some very well-known brands in the ENDS market, including e-liquid and hardware brands.

    He has keen interest in the analysis of ENDS products and together with Xyfil’s partner laboratory, he has played a key role in guiding the development of seven analytical methods – using various techniques such as LC-MS, GC-MS, GC-FID, HPLC-UV, ICP-OES, and KF – that are specifically developed and validated for ENDS market. He has also developed and improved upon emissions collection methods that mimic real-world usage patterns; this system is currently under the UK patent process. He also authored various documents on behalf of the company including CLP classification of ENDS products, the first publicly available document with complete and accurate classification for e-liquid products.

    He also regularly engages in scientific correspondence with various government agencies such as MHRA, European Chemicals Agency, and EU Committee for Risk Assessment providing some crucial contribution on various topics including regulation, toxicological assessment and harmonised classification of chemicals used in ENDS industry. Among other achievements, he has successfully thwarted attempts to incorrectly classify propylene glycol as a respiratory irritant, at the EU level.

    Prior to Xyfil, Dilip supervised and trained several BSc, MSc, MRes students and a PhD student in their individual research projects at the University of Central Lancashire (UCLan). He was awarded a PhD in Neuroscience from UCLan for his work that elucidated some of the cellular and extracellular processes involved in distinct modes of synaptic exocytosis in the Central Nervous System. For his PhD, he received scholarship under the reputable Overseas Research Students Associate Scheme.  Dilip earned a First Class BSc degree in Molecular and Cellular Biology from UCLan. He has presented papers at many international conferences.

  • Matthew Bland

    Business Development Director Eliquid Solutions

    Matthew moved into the city where he started his career in Financial Services for a number of both Insurance & Broking houses in London   (City).  Before his current position as Business Development Director at Eliquid Solutions he held a variety of commercial posts including  Senior Commercial Accounts, Consultant & Managing Director. Matthew also loves all things water, snow or ice. Swimming, sailing, skiing and foreign travel are his passions, but when he’s not doing any of these he and his colleagues at Eliquid Solutions are continually striving for improvement in this FMCG sector.  Matthew has been involved in the ecigarette market and category since 2012.

  • Gregory G. Brown

    General Counsel Space Jam Juice

    Gregory G. Brown is General Counsel and Corporate Secretary of Space Jam Juice, LLC, a leading e-liquid and e-cigarette device manufacturer and distributor.  Headquartered in the United States, Space Jam Juice, LLC manufactures and distributes premium e-liquids and devices through out the world.

    Brown has been a practicing business and corporate lawyer for 30 years and a partner in the Southern California law firm of Brown & Charbonneau, LLP.  Brown has focused much of his experience to a variety of emerging and manufacturing industries, including the e-cigarette industry.  Since early 2015, Brown has been deeply involved in worldwide e-cigarette regulations and issues, including the EU Tobacco Products Directive and the US Food & Drug Administrations deeming regulations.  Brown has spoken and written to industry and stakeholders throughout his career, most recently as a panelist at the June 2017 ENDS Conference in London.

    Brown is a highly regarded business lawyer and has received countless awards and recognition from his peers.  He has been named one of the Forbes Magazine’s “Legal Leaders” and has been recognized as one of the “Best Lawyers in America” by the US News and World Report. He has been awarded the highly coveted “AV Preeminent Rating” by Martindale – Hubbell, which is the highest possible rating, signifying that his peers rank him at the highest level of professional excellence.  Brown has also been named to Super Lawyers for the last eight years, which signifies the top 5% of lawyers.  With extensive trial experience, Brown was accepted into to the American Board of Trial Advocates and is a Board Certified Trial Specialist.

    Brown graduated from the University of San Diego School of Law in 1987 where he was named to the San Diego Law Review and was a founding editor the Journal of Contemporary Legal Issues.  Brown has also received extensive Mediation and Alternative Dispute Resolution training and experience, having graduated from the renowned Strauss Institute for Dispute Resolution in Malibu, California.

    Brown grew up in Southern California and is married with 5 children. 

  • Jo Davis

    Copy Advice Executive Committee of Advertising Practice (CAP)

    Jo joined the ASA in 2010 and spent five years working in the Complaints department, before moving to CAP to join the Copy Advice team in 2015.  Jo specialises in giving advice relating to the marketing of electronic cigarettes, beauty, weight control and travel products and services.

  • David Dawit

    Chief Scientific Officer Eos Scientific

    My background is chemistry. I have a BSc in Chemistry, MSc in Analytical and Environmental Chemistry and a PhD in Biogeochemistry. My career spans over 25 years, mostly as analytical chemist. I have worked for academic, research and commercial enterprises. I have written and published a number of scientific articles in highly reputable journals. I became a full member (MRSC) of the Royal Society of Chemistry in 2014.I am currently lead for all scientific activities including quality control and regulatory submission. I also actively participate in new products development. We are among the leaders in the industry for quality and innovative products which are based on sound and ground breaking scientific principles. I also work as postgradaute supervisor for two international universities and a reviewer for a number of journals. My experience with electronic cigarette regulation started in 2014 just after the EU law was passed. As this regulation was new, at first requirements, especially for analytical and toxicology work were not clear. This has now substantially been improved but still a lot remains to be done before we have a well-established framework. When I started there was a lot of confusion on what kind of analytical procedures should one follow to satisfy the EU Tobacco Product Directive (TPD) interpretation in the UK. The Medicine and Health Regulatory Authority (MHRA) have been helpful in this regard. With close communication with them we have been able to design, develop our analytical methods and toxicology data requirements. At Eos Scientific in a relatively short period of time we have developed and validated a number of methods that are fit for purpose for e-liquid and vapour testing. We have also trained chemists and toxicology researchers to meet the demand for a large section of the industry in the UK. Our experience in this regard will benefit upcoming regulatory requirements in different parts of the world. Our technical services include method development and validation, assisting with threshold limits setting as well as reliable advice on toxicology, reformulation and product development.

  • Charles Ducker

    Principal Chemist/Group Leader Eurofins Medical Device Testing

    Dr. Charles Ducker is a Principal Chemist/Group Leader for Eurofins Medical Device Testing Extractables and Leachables group where he performs extractables and leachables testing using LC/MS-TOF, LC/MS/MS, GC/MS, and ICP-OES technology. Specializing in LC/MS analysis, Dr. Ducker has 13 years of experience in the biotech industry and has served as the lead scientist for two significant drug discovery programs. Dr. Ducker earned a Ph.D. in Biochemistry/Molecular Biology from The Pennsylvania State University, as well as a B.S. in Biology from Millersville University.

  • Dr. Ian M. Fearon

    Principal Scientist and Head of Clinical Research British American Tobacco

    Ian is a Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development center in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation.  Prior to joining BAT in 2008, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor at McMaster University in Hamilton, Canada.  Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters and generating over 1,900 citations.

  • Scott Fletcher

    Director of Analytical Services Hall Analytical

    Scott is the Director of Analytical Services at Crawford Scientific where he heads up their specialist MS based laboratory, Hall Analytical, in Manchester, UK.

    Hall Analytical has a long association with e-cigarette analysis and development with over 10 years experience of preforming analytical testing on the very early cigalike prototypes.

    Before this he spent many years working as a professional trainer and consultant in analytical chemistry and prior to that he worked in the pharmaceutical industry in the incredibly analogous field of developing dry powder inhalers!

    Scott sits on the Separation Science Committee of the Royal Society of Chemistry, of whom he is a Fellow, and on the Editorial Advisory Board of various Separation Science publications and is regular speaker at national and internal conferences. 

  • Charles Hamshaw-Thomas

    Head of Corporate and Legal Affairs – Europe and Board Member at UK Vaping Industry Association (UKVIA) Nicopure Labs

    Charles Hamshaw-Thomas is the Head of Corporate and Legal Affairs for Europe at Nicopure Labs.

    Charlie was previously Corporate Affairs, Business Development and Legal Director for E-Lites, the brand at the forefront of the UK vaping industry’s explosive early growth beginning in 2012. Prior to that, he was Principal of CSR Solutions, a corporate social responsibility consultancy business.

    Having qualified as a lawyer in London with Slaughter and May, Charlie subsequently held senior management positions with some of the UK’s largest public companies (ITG, Beazer Homes, and Hanson Trust) where he has worked across different functional areas - including legal, company secretarial, business development, and corporate affairs — and in various markets throughout the world.

  • Beryl Keeley

    E-Cigarette Notification Scheme Lead Medicines and Healthcare products Regulatory Agency (MHRA)

    Beryl Keeley has a background in biochemistry and has worked in various areas in Government and previously in the pharmaceutical industry.  Currently Beryl is leading the UK implementation of the Tobacco Products Directive notification scheme for e-cigarettes at the Medicines and Healthcare products Regulatory Agency.

    Previously Beryl has been Advertising Standards and Outreach Unit Manager within the Agency’s Vigilance and Risk Management of Medicines Division. The Unit has responsibility for the regulation of medicines advertising in the UK and for production of Drug Safety Update.

  • Patricia I. Kovacevic

    General Counsel and Chief Compliance Officer Nicopure Labs LLC

    Patricia I. Kovacevic is the general counsel and chief compliance officer of Nicopure Labs LLC, the leading e-liquid and vaping device manufacturer of U.S.- made Halo, Purity and eVo e-liquids and Triton and G6 devices. With extensive U.S. and international industry experience, Kovacevic held senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Kovacevic serves on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to the Council for Burley Tobacco. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages.

  • Derek Mariner

    CORESTA E-Vapour Subgroup CORESTA

    CORESTA (Cooperation Centre for Scientific Research Relative to Tobacco, www.coresta.org) is an association founded in 1956, ruled by French law, the purpose being to promote international cooperation in scientific research relative to tobacco and its derived products.  CORESTA Full Members are organisations (companies, institutes, laboratories, associations) having R&D activities related to tobacco or its derived products (including e-vapour products), whether in the plant field (tobacco agronomy, breeding, phytopathology) or in the fields of manufacturing, chemistry, metrology, or materials (paper, filters, aerosols, etc.).

    The CORESTA E- Vapour SubGroup was formed in 2013 (originally a Task Force) and currently has members from 45 different organisations representing e-cigarette and e-liquid manufacturers, academia, regulators, equipment suppliers, and testing laboratories. It has published the following documents and Recommended Methods (all available on the CORESTA website):

    E-Cigarettes: A Brief Description of History, Operation and Regulation. Reference Report - February 2014
    E-Cigarettes: Assessment of Analytical Literature from 55 Studies Published Worldwide prior to November 2013 on Commercial E-Cigarettes. Reference Report - May 2014
    E-Liquid Preliminary Proficiency Study. Technical Report - March 2015
    2014 Electronic Cigarette Aerosol Parameters Study. Technical Report - March 2015
    2015 Collaborative Study for Determination of Glycerin, Propylene Glycol, Water and Nicotine in Collected Aerosol of E-Cigarettes. Technical Report - March 2017
    CRM 81: Routine analytical machine for e-cigarette aerosol generation and collection - definitions and standard conditions
    CRM 84: Determination of glycerin, propylene glycol, water, and nicotine in the aerosol of e-cigarettes by gas chromatographic analysis
    Guide No. 18: Sample Handling and Sample Collection of E-Cigarettes and E-Vapour Generating Products

    The SubGroup has presented at two FDA e-cigarette workshops, and at e-cigarette events in the UK, France and Germany.  It participates fully in ISO and CEN standard development activity.

    Dr Derek Mariner is Principal Scientist in the Analytical Development Centre of British American Tobacco R&D.  His BSc was in Biochemistry and his PhD was in the mechanism of nicotine uptake during smoking and consequently covered a range of disciplines including analytical chemistry, respiratory physiology and aerosol science. He has worked in the tobacco industry for 33 years in a range of roles in R&D and on secondment in Legal and External Affairs.  Derek has also worked on behalf of BAT in CORESTA in various Subgroups and Task Forces, from agrochemicals to environmental tobacco smoke via human smoking behaviour.  He has served as President of the CORESTA Scientific Commission, and currently represents BAT on the Board of CORESTA.  Derek has also worked in BSI and as an Expert in several ISO Working Groups.  He is currently Convenor of ISO TC126 SC3 WG2 “Routine Analytical E-cigarette Vaping Machine”.  Derek is also a Chartered Chemist and Fellow of the Royal Society of Chemistry.  For the purposes of this presentation, Derek is speaking on behalf of the CORESTA E-Vapour Subgroup.

  • Willie McKinney

    Vice President Regulatory Sciences Altria Client Services (ALCS)

    Willie J. McKinney, Ph.D., D.A.B.T., serves as Vice President, Regulatory Sciences, for Altria Client Services (ALCS) in Richmond, Virginia. In this role, he leads a team that develops scientific evaluation and regulatory science strategies for Altria's family of companies.

    Dr. McKinney has held a variety of positions with increasing responsibilities within the Altria family of companies. He served as Senior Director, Product Integrity and Regulatory Reporting, where he led a team that develops scientific evaluation and regulatory submission strategies for Altria's family of companies; Director, Strategic Product Planning, where he provided operational and strategic support; Senior Manager, Cellular & Molecular Biology Group; and as a visiting scientist at the Institute for Biologische Forschung GmbH (INBIFO) in Köln, Germany.

    Before joining the Altria family of companies in 1998, Dr. McKinney held a variety of academic and research roles, including working as an Associate Research Scientist, Nelson Institute of Environmental Medicine, NYU Medical Center, Tuxedo, N.Y., and as a Graduate Research Assistant at the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill. He also held Toxicology Intern and Research Assistant roles with several government agencies. Dr. McKinney is board certified in Toxicology by the American Board of Toxicology. He has published numerous professional articles related to his research and work, and has presented before various scientific organizations. He holds a BS degree in Biology from Xavier University, an MS in Biology from North Carolina Central University, and a PhD in Environmental Toxicology from the University of North Carolina at Chapel Hill. He serves on the Higher Achievement Board and on the Richmond Higher Achievement Advisory Board.

  • David McLaughlin

    Director, Business Development Elucid8

    David is director of business development at Elucid8, a speciality consultancy company that brings together experts with over 90 years of industry experience in nicotine products and offers tailored assistance in product development, consumer research, patent/literature reviews and regulatory compliance.

    Prior to establishing Elucid8, David was Director of R&D for ‘Next Generation Products’  within a major FMCG company where he has a proven track record of developing high performing teams and bringing business-relevant inhalable products to market within a multicultural environment.

    David holds a BSc in Chemistry from University of St.Andrews; a PhD in drug delivery from Queens University of Belfast; a MBA from Ulster University and has published several patents in fields of novel products and technology.

  • Daniel Merrill

    Study Director Eurofins Medical Device Testing

    Daniel Merrill, received his Bachelors of Biology with emphasis in Chemistry from Richard Stockton College of NJ and has further received his Master of Business Administration from Rider University.  He has seven years of experience focusing on regulatory testing and requirements.  Daniel has served as Scientist and Study Director.  In his current role of Study Director he oversees the conduct of a variety of toxicology studies.  He has extensive knowledge in the conduct of inhalation study.  He has designed, conducted and directed inhalation studies on many different types of products across many different industries, including pilot work with e-cigarettes.   

  • Glenn J. Myatt, Ph.D.

    Chief Scientific Officer Leadscope

    Dr. Myatt is one of the founders and is currently the Chief Scientific Officer of Leadscope, Inc. He has over 25 years of experience researching and developing in silico solutions. He is currently the principal investigator on two US National Institutes of Health research grants and has co-authored 21 publications (including a number of papers related to ICH M7), three books as well as five book chapters.

  • Dr. Daniel Norwood

    Executive Partner SCIO Analytical & Senior Consultant at Smithers Rapra

    Dr. Norwood is a Distinguished Research Fellow in Analytical Development for Boehringer Ingelheim Pharmaceuticals, Inc., and has held senior industry positions at Magellan Laboratories and the Glaxo Research Institute. He chaired the PQRI working group on Leachables and Extractables in Orally Inhaled and Nasal Drug Products, and is currently a member of the PQRI working group for Parenteral and Ophthalmic Drug Products. He has served on the Board of the Extractables Leachables Safety Information Exchange, and is a member of the USP Packaging, Storage and Distribution Expert Committee where he chairs the subcommittee on extractables and leachables.

  • Tom Pruen

    Chief Scientific Officer Electronic Cigarette Industry Trade Association

    Tom Pruen is ECITA’s Chief Scientific Officer and a graduate of the University of the West of England, having attained his BSc in Applied Chemical Science in 1998.

    Tom has been involved with the electronic cigarette since the early days of their introduction into the UK, starting his career first as an advocate, and then becoming an integral part of the industry’s first trade association ECITA as its highly-respected scientific spokesperson.

    Tom’s contribution to the vaping industry includes having been one of the first scientists in the industry to identify the importance of screening for Diacetyl and its associated products, he was a the principle author of PAS54115, the first publicly available specification for e-liquids and hardware products, and he has given evidence at the Welsh Assembly in defence of their suitability as a harm reduction tool. Tom frequently consults with the MHRA, the ASA, and other regulatory bodies, as part of his drive to share information in order to progress the industry to the benefit of the wider public.

  • Pete Watts

    Director of Toxicology bibra toxicology advice and consulting

    Pete is a European and RSB/BTS registered toxicologist with 39 years’ experience in reviewing and critically evaluating toxicological data and other scientific information.  He has a keen interest in the e-cigarette sector, focusing on the safety of ingredients, emissions and extractables and leachables. Pete also works closely with a wide portfolio of companies in the pharma, medical devices and packaging sectors. Responsibilities include health risk assessment of pharmaceutical impurities, contaminants and excipients, PDE setting, and biocompatibility assessment of medical devices in line with the EU Directive, ISO 10993 and FDA guidance.

  • Richard Young

    Principal Toxicologist bibra toxicology advice and consulting

    Richard is a RSB/BTS and European Registered Toxicologist (ERT) and has been working as a desk-based toxicologist at bibra for 15 years.  He is also a Member of the Royal Society of Biology (MRSB), the British Toxicology Society (BTS) and the Chemical Hazards Communication Society (CHCS). His special interests include the pragmatic application of risk assessment methodology to mammalian toxicity data sets, in order to derive robust conclusions on toxicological acceptability of exposures and on health risks to exposed populations. In recent years he has been helping companies assess the potential human health effects of NTNDDs. This has included assisting in the production of toxicity monographs on over 300 e-liquid ingredients and proposing toxicologically tolerable levels for key e-liquid ingredients and e-cig emissions. 

  • Nele Zgavc

    Programme Manager, Governance & Resilience - Healthcare British Standards Institute (BSI)

    Nele Zgavc works predominantly in the healthcare sector of the British Standards institute (BSI). BSI is the UK's National Standards Body representing UK economic and social interests across all European and international standards organizations. As the first national standards body, BSI is highly regarded in the standards world and often leads the way in newly developed areas. In 2015 we were involved in the creation of PAS 54115 which was the first UK initiative to provide a standardized guide on Vaping products, including electronic cigarettes, e-liquids, e-shisha and directly-related products.